Contrast-enhanced in vivo imaging of breast and prostate cancer cells by MRI

Olga Rodriguez, Stanley Fricke, Christopher Chien, Luis Dettin, John VanMeter, Erik Shapiro, Hai Ning Dai, Mathew Casimiro, Lilia Ileva, John Dagata, Michael D. Johnson, Michael P. Lisanti, Alan Koretsky, Chris Albanese

Research output: Research - peer-reviewArticle

  • 39 Citations

Abstract

The development of effective cancer therapies has been hampered, in part, by the inability to noninvasively follow tumor progression from the initial cancerous lesion through to metastasis. We have previously shown that superparamagnetic iron oxide particles can be used as magnetic resonance imaging contrast agents to label embryonic, mesenchymal and hematopoietic stem cells in vivo. Improving the capacity to non-invasively image cancer progression is an appealing method that could be useful for assessing the efficacy of anticancer therapies. We have established that human prostate (LNCaP, DU145, PC3), rodent prostate (TRAMPC1, YPEN-1), human breast (MDA-MB-231) and mouse mammary (Myc/VEGF) cancer cell lines were readily labeled by fluorescent superparamagnetic sub-micron particles of iron oxide (MPIOs). The MPIOs were essentially inert with respect to cell proliferation and tumor formation. Fluorescence stereomicroscopy and three dimensional magnetic resonance imaging (MRI) determined that subcutaneous, intramuscular or orthotopically implanted labeled cancer cells could be imaged, in vivo, despite in some cases being undetectable by manual palpation. The MPIO-labeled cancer cells could also be imaged, in vivo, at least 6 weeks after implantation. The fluorescent MPIOs further allowed for the ex vivo identification of tumors cells from histological sections. This study demonstrates the feasibility of using fluorescent MPIOs in prostate and breast cancer cell lines as both a negative contrast agent for in vivo MRI as well as a fluorescent tumor marker for optical imaging in vivo and ex vivo.

LanguageEnglish (US)
Pages113-119
Number of pages7
JournalCell Cycle
Volume5
Issue number1
StatePublished - Jan 1 2006
Externally publishedYes

Profile

Prostatic Neoplasms
Magnetic Resonance Imaging
Breast Neoplasms
Neoplasms
Magnetic resonance
Cells
Imaging techniques
ferric oxide
Tumors
Contrast Media
Prostate
Breast
Cell Line
Therapeutics
Cell proliferation
Tumor Biomarkers
Stem cells
Vascular Endothelial Growth Factor A
Labels
Fluorescence

Keywords

  • Breast cancer
  • Fluorescence
  • MRI
  • Nanoparticle
  • Prostate cancer
  • Superparamagnetic
  • Xenograft

ASJC Scopus subject areas

  • Cell Biology
  • Biochemistry
  • Molecular Biology

Cite this

Rodriguez, O., Fricke, S., Chien, C., Dettin, L., VanMeter, J., Shapiro, E., ... Albanese, C. (2006). Contrast-enhanced in vivo imaging of breast and prostate cancer cells by MRI. Cell Cycle, 5(1), 113-119.

Contrast-enhanced in vivo imaging of breast and prostate cancer cells by MRI. / Rodriguez, Olga; Fricke, Stanley; Chien, Christopher; Dettin, Luis; VanMeter, John; Shapiro, Erik; Dai, Hai Ning; Casimiro, Mathew; Ileva, Lilia; Dagata, John; Johnson, Michael D.; Lisanti, Michael P.; Koretsky, Alan; Albanese, Chris.

In: Cell Cycle, Vol. 5, No. 1, 01.01.2006, p. 113-119.

Research output: Research - peer-reviewArticle

Rodriguez, O, Fricke, S, Chien, C, Dettin, L, VanMeter, J, Shapiro, E, Dai, HN, Casimiro, M, Ileva, L, Dagata, J, Johnson, MD, Lisanti, MP, Koretsky, A & Albanese, C 2006, 'Contrast-enhanced in vivo imaging of breast and prostate cancer cells by MRI' Cell Cycle, vol 5, no. 1, pp. 113-119.
Rodriguez O, Fricke S, Chien C, Dettin L, VanMeter J, Shapiro E et al. Contrast-enhanced in vivo imaging of breast and prostate cancer cells by MRI. Cell Cycle. 2006 Jan 1;5(1):113-119.
Rodriguez, Olga ; Fricke, Stanley ; Chien, Christopher ; Dettin, Luis ; VanMeter, John ; Shapiro, Erik ; Dai, Hai Ning ; Casimiro, Mathew ; Ileva, Lilia ; Dagata, John ; Johnson, Michael D. ; Lisanti, Michael P. ; Koretsky, Alan ; Albanese, Chris. / Contrast-enhanced in vivo imaging of breast and prostate cancer cells by MRI. In: Cell Cycle. 2006 ; Vol. 5, No. 1. pp. 113-119
@article{acfd66081705432db12fceeb2d616b54,
title = "Contrast-enhanced in vivo imaging of breast and prostate cancer cells by MRI",
abstract = "The development of effective cancer therapies has been hampered, in part, by the inability to noninvasively follow tumor progression from the initial cancerous lesion through to metastasis. We have previously shown that superparamagnetic iron oxide particles can be used as magnetic resonance imaging contrast agents to label embryonic, mesenchymal and hematopoietic stem cells in vivo. Improving the capacity to non-invasively image cancer progression is an appealing method that could be useful for assessing the efficacy of anticancer therapies. We have established that human prostate (LNCaP, DU145, PC3), rodent prostate (TRAMPC1, YPEN-1), human breast (MDA-MB-231) and mouse mammary (Myc/VEGF) cancer cell lines were readily labeled by fluorescent superparamagnetic sub-micron particles of iron oxide (MPIOs). The MPIOs were essentially inert with respect to cell proliferation and tumor formation. Fluorescence stereomicroscopy and three dimensional magnetic resonance imaging (MRI) determined that subcutaneous, intramuscular or orthotopically implanted labeled cancer cells could be imaged, in vivo, despite in some cases being undetectable by manual palpation. The MPIO-labeled cancer cells could also be imaged, in vivo, at least 6 weeks after implantation. The fluorescent MPIOs further allowed for the ex vivo identification of tumors cells from histological sections. This study demonstrates the feasibility of using fluorescent MPIOs in prostate and breast cancer cell lines as both a negative contrast agent for in vivo MRI as well as a fluorescent tumor marker for optical imaging in vivo and ex vivo.",
keywords = "Breast cancer, Fluorescence, MRI, Nanoparticle, Prostate cancer, Superparamagnetic, Xenograft",
author = "Olga Rodriguez and Stanley Fricke and Christopher Chien and Luis Dettin and John VanMeter and Erik Shapiro and Dai, {Hai Ning} and Mathew Casimiro and Lilia Ileva and John Dagata and Johnson, {Michael D.} and Lisanti, {Michael P.} and Alan Koretsky and Chris Albanese",
year = "2006",
month = "1",
volume = "5",
pages = "113--119",
journal = "Cell Cycle",
issn = "1538-4101",
publisher = "Landes Bioscience",
number = "1",

}

TY - JOUR

T1 - Contrast-enhanced in vivo imaging of breast and prostate cancer cells by MRI

AU - Rodriguez,Olga

AU - Fricke,Stanley

AU - Chien,Christopher

AU - Dettin,Luis

AU - VanMeter,John

AU - Shapiro,Erik

AU - Dai,Hai Ning

AU - Casimiro,Mathew

AU - Ileva,Lilia

AU - Dagata,John

AU - Johnson,Michael D.

AU - Lisanti,Michael P.

AU - Koretsky,Alan

AU - Albanese,Chris

PY - 2006/1/1

Y1 - 2006/1/1

N2 - The development of effective cancer therapies has been hampered, in part, by the inability to noninvasively follow tumor progression from the initial cancerous lesion through to metastasis. We have previously shown that superparamagnetic iron oxide particles can be used as magnetic resonance imaging contrast agents to label embryonic, mesenchymal and hematopoietic stem cells in vivo. Improving the capacity to non-invasively image cancer progression is an appealing method that could be useful for assessing the efficacy of anticancer therapies. We have established that human prostate (LNCaP, DU145, PC3), rodent prostate (TRAMPC1, YPEN-1), human breast (MDA-MB-231) and mouse mammary (Myc/VEGF) cancer cell lines were readily labeled by fluorescent superparamagnetic sub-micron particles of iron oxide (MPIOs). The MPIOs were essentially inert with respect to cell proliferation and tumor formation. Fluorescence stereomicroscopy and three dimensional magnetic resonance imaging (MRI) determined that subcutaneous, intramuscular or orthotopically implanted labeled cancer cells could be imaged, in vivo, despite in some cases being undetectable by manual palpation. The MPIO-labeled cancer cells could also be imaged, in vivo, at least 6 weeks after implantation. The fluorescent MPIOs further allowed for the ex vivo identification of tumors cells from histological sections. This study demonstrates the feasibility of using fluorescent MPIOs in prostate and breast cancer cell lines as both a negative contrast agent for in vivo MRI as well as a fluorescent tumor marker for optical imaging in vivo and ex vivo.

AB - The development of effective cancer therapies has been hampered, in part, by the inability to noninvasively follow tumor progression from the initial cancerous lesion through to metastasis. We have previously shown that superparamagnetic iron oxide particles can be used as magnetic resonance imaging contrast agents to label embryonic, mesenchymal and hematopoietic stem cells in vivo. Improving the capacity to non-invasively image cancer progression is an appealing method that could be useful for assessing the efficacy of anticancer therapies. We have established that human prostate (LNCaP, DU145, PC3), rodent prostate (TRAMPC1, YPEN-1), human breast (MDA-MB-231) and mouse mammary (Myc/VEGF) cancer cell lines were readily labeled by fluorescent superparamagnetic sub-micron particles of iron oxide (MPIOs). The MPIOs were essentially inert with respect to cell proliferation and tumor formation. Fluorescence stereomicroscopy and three dimensional magnetic resonance imaging (MRI) determined that subcutaneous, intramuscular or orthotopically implanted labeled cancer cells could be imaged, in vivo, despite in some cases being undetectable by manual palpation. The MPIO-labeled cancer cells could also be imaged, in vivo, at least 6 weeks after implantation. The fluorescent MPIOs further allowed for the ex vivo identification of tumors cells from histological sections. This study demonstrates the feasibility of using fluorescent MPIOs in prostate and breast cancer cell lines as both a negative contrast agent for in vivo MRI as well as a fluorescent tumor marker for optical imaging in vivo and ex vivo.

KW - Breast cancer

KW - Fluorescence

KW - MRI

KW - Nanoparticle

KW - Prostate cancer

KW - Superparamagnetic

KW - Xenograft

UR - http://www.scopus.com/inward/record.url?scp=33645276597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645276597&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 113

EP - 119

JO - Cell Cycle

T2 - Cell Cycle

JF - Cell Cycle

SN - 1538-4101

IS - 1

ER -